USPTO serial 98821547
STEMLOGIC
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- WELLS,KELLEY L
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with STEMLOGIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Francisco, CA
San Francisco, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Isaac M. Fine
Isaac M. Fine KPPB LLP180 E. Ocean Blvd., Suite 1030Long Beach, CA 90802United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF CHEMOTHERAPY; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF RADIATION THERAPY; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF TARGETED CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF TARGETED CANCER TREATMENTS, NAMELY, TYROSINE KINASE INHIBITORS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING SIDE EFFECTS OF IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING GASTROINTESTINAL DISTRESS, MUCOCITIS, NAUSEA, VOMITING AND DIARRHEA; PHARMACEUTICAL PREPARATIONS FOR STIMULATING APPETITE; PHARMACEUTICAL PREPARATIONS FOR PREVENTING WEIGHT LOSS; PHARMACEUTICAL PREPARATIONS FOR PROTECTING BONE MARROW AND THE PRODUCTION OF BONE MARROW; PHARMACEUTICAL PREPARATIONS FOR PROTECTING STEM CELLS AND STIMULATING THE PRODUCTION OF STEM CELLS; PHARMACEUTICAL PREPARATIONS FOR INCREASING RESILIENCY OF STEM CELLS, INCREASING THE NUMBER OF STEM CELLS, AND PREVENTING THE REDUCTION OF STEM CELL POPULATIONS; PHARMACEUTICAL PREPARATIONS FOR PROTECTING BLOOD CELLS, ALLEVIATING ANEMIA, NEUTROPENIA, AND THROMBOCYTOPENIA, AND ALLEVIATING LOW BLOOD COUNT; PHARMACEUTICAL PREPARATIONS FOR ALLEVIATING DOSE LIMITING SIDE EFFECTS OF CANCER TREATMENTS, CHEMOTHERAPY, RADIATION THERAPY, TARGETED CANCER TREATMENTS AND IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF CHEMOTHERAPY; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF RADIATION THERAPY; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF TARGETED CANCER TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF TARGETED CANCER TREATMENTS, NAMELY, TYROSINE KINASE INHIBITORS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISTRESS, MUCOCITIS, NAUSEA, VOMITING AND DIARRHEA; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF LOSS OF APPETITE; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF WEIGHT LOSS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF BONE MARROW DAMAGE; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF STEM CELL DAMAGE AND REDUCTION OF STEM CELL POPULATIONS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF BLOOD CELL DAMAGE, ANEMIA, NEUTROPENIA, THROMBOCYTOPENIA AND LOW BLOOD COUNT; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF DOSE LIMITING SIDE EFFECTS OF CANCER TREATMENTS, CHEMOTHERAPY, RADIATION THERAPY, TARGETED CANCER TREATMENTS AND IMMUNOTHERAPY TREATMENTS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF SIDE EFFECTS OF CANCER TREATMENTS, CHEMOTHERAPY, RADIATION THERAPY, TARGETED CANCER TREATMENTS AND IMMUNOTHERAPY TREATMENTS, NAMELY, REDUCED FERTILITY; FERTILITY ENHANCEMENT PREPARATIONS; PHARMACEUTICAL PREPARATIONS FOR SUPPORTING STEM CELL HEALTH AND PRODUCTION; PHARMACEUTICAL PREPARATIONS FOR SUPPORTING STEM CELL HEALTH AND PRODUCTION, NAMELY FOR STIMULATING UTERINE, BONE MARROW AND GASTROINTESTINAL TRACK STEM CELL PRODUCTION; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF RADIATION EXPOSURE | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 19, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 19, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 12, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 12, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 12, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 17, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 22, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 22, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 18, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 18, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 18, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 16, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 26, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 26, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 25, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 25, 2024 | NWAP | NEW APPLICATION ENTERED | — |